Thyroid Disease CARE Act of 2025

The Thyroid Disease CARE Act of 2025 (HR6897) was introduced in the House on December 18, 2025, and subsequently referred to the House Committee on Energy and Commerce. This bill, sponsored by Rep. Stevens [D-MI-11] with one cosponsor, aims to advance research, promote awareness, and improve healthcare for thyroid disease. Its current status as 'Referred to committee' indicates it is in the early stages of the legislative process. The bill authorizes $30,000,000 annually for fiscal years 2026 through 2030 to support research and related activities concerning thyroid disease. This funding is specifically for investigating root causes, improving diagnostic techniques and treatments, enhancing thyroid cancer care and survivorship, understanding symptom management, and assessing disparities. It is crucial to note that this is an authorization, not an appropriation; actual funding will depend on subsequent appropriations bills. The money, if appropriated, would flow to the Secretary (likely HHS/NIH) who would then conduct or support research through grants and contracts to academic institutions, research organizations, and potentially private companies. Structural winners, should this bill advance and receive appropriations, would primarily be companies involved in medical diagnostics, research tools, and pharmaceutical development for thyroid conditions. Companies like Quest Diagnostics ($DGX) and Labcorp ($LH) are positioned to benefit from increased demand for diagnostic testing and potential involvement in research studies. Thermo Fisher Scientific ($TMO) would see increased demand for its research equipment and consumables. Abbott Laboratories ($ABT) could benefit from its diagnostics segment, while Illumina ($ILMN) may see increased demand for genomic sequencing related to root cause research. Hologic could also benefit from its focus on women's health and diagnostics, particularly concerning thyroid cancer. Recent market data shows mixed performance for these companies. Over the last 7 days, $ABT is up +2.18%, while $DGX is down -4.02%, $LH is down -4.48%, and $TMO is down -8.91%. $ILMN is down -2.73% over the same period, while is up +0.56% over the last 7 days. These movements are likely influenced by broader market trends and company-specific news unrelated to this early-stage bill. The bill's legislative path involves committee consideration, potential floor votes in the House and Senate, and ultimately presidential assent. Given its early stage and the need for subsequent appropriations, any direct market impact is speculative at this time. No recent Presidential Actions provided are directly relevant to the Thyroid Disease CARE Act of 2025. The presidential memoranda issued on April 20, 2026, focus on energy and infrastructure sectors, invoking the Defense Production Act, and do not intersect with healthcare research funding.